BRIM Biotechnology, Inc. (6885.TW) stock: key figures, P/E, revenue and dividend

Health Care · Taiwan

Price
27.85 TWD
Market cap
3.66 bn TWD
P/E (2025)
–
P/S (2025)
667.33
Dividend yield
0.00 %
Net margin
-7,949.95 %
Return on equity (ROE)
–
Return on assets (ROA)
–

BRIM Biotechnology, Inc. financials

Fiscal year20242025
Revenue333,000.00 TWD5.49 m TWD
Gross profit22,000.00 TWD1.25 m TWD
Operating income-344.79 m TWD-452.97 m TWD
EBIT-315.38 m TWD-450.41 m TWD
Net income-315.47 m TWD-436.45 m TWD
Diluted EPS – continuing operations-2.40 TWD–

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About BRIM Biotechnology, Inc.

BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan. The company's lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease. It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for the treatment of glaucoma; BRM412, an anti-angiogenic eye drop that has completed Phase 2 clinical trial to treat wet age-related macular degeneration; and BRM521, a PEDF-derived short peptide that is in pre-clinical trial to relieve and repair tissue damage caused by osteoarthritis. BRIM Biotechnology, Inc. was founded in 2013 and is based in Taipei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.